SCHEMBL7699488

SCHEMBL7699488

COC(=O)c1c(C)[nH]c2ccc(OC)c(Cc3ccccc3)c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
MAPT P10636 3/20 0.50
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2D6 P10635 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
TSHR P16473 1/20 0.50
NFKB1 P19838 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
HIF1A Q16665 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
NR4A2 P43354 1/20 0.48
HSP90AA1 P07900 1/20 0.45
LMNA P02545 2/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7698761 0.87 ALDH1A1 (0.51) ALDH1A1MAPTCYP1A2CYP3A4CYP2D6
SCHEMBL7697885 0.86 MTNR1A (0.44) ALDH1A1MAPTCYP1A2CYP3A4CYP2D6
SCHEMBL7693001 0.82 AKR1C2 (0.49) ALDH1A1MAPTCYP1A2CYP3A4CYP2C19
SCHEMBL7699984 0.80 TRPC5 (0.42) ALDH1A1TSHRLMNAPOLBGAA
SCHEMBL7693551 0.75 MDM4 (0.38) ALDH1A1LMNAPOLBGAAKMT2A
SCHEMBL7698626 0.74 GAA (0.49) ALDH1A1MAPTCYP1A2CYP3A4CYP2C19
SCHEMBL27554752 0.73 RAB9A (0.51) ALDH1A1MAPTCYP1A2CYP3A4CYP2D6
SCHEMBL7694495 0.73 HSP90AA1 (0.44) ALDH1A1MAPTCYP1A2CYP3A4CYP2D6
SCHEMBL7931226 0.73 MME (0.40) CYP1A2PTPN5
SCHEMBL7699710 0.72 AKR1C2 (0.46) ALDH1A1MAPTCYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002020478-A1 N-BENZYLINDOLE-3-ACETIC ACID DERIVATIVES FOR USE IN THE TREATMENT OF DRUG RESISTAN CANCER DUBLIN CITY UNIVERSITY (IE) 2002-03-14 WO disclosed